In back-to-back trial disasters, Gemphire now says it shuttered a trial after seeing patients' fatty liver disease get worse
Four days after Gemphire saw its shares $GEMP crushed by news of an FDA demand for additional safety data on its only drug before advancing …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
